Radcliffe Medical Education is hosting a symposium entitled 'Challenges in ATTR Amyloidosis: An Expert Debate' at the Heart Failure Association (HFA) in Lisbon, PT, on Saturday 11 May 2024 at 12:30 - 13:30 UTC+1. 
 

Overview

In this symposium we join Prof Thibaud Damy (Creteil, FR), Dr Esther González López (Madrid, SP), Dr João R. Agostinho (Lisbon, PT) and Dr Ahmad Masri (Portland, USA) for a programme centred around three distinctive challenges facing physicians when diagnosing and treating ATTR-CM patients. 

Individuals participating in this session will leave with a comprehensive understanding of the signs and symptoms of ATTR amyloidosis. 

Challenges in ATTR Amyloidosis: An Expert Debate’s programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
 

Learning Objectives 

After attending this symposium, physicians will be able to:

• Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
• Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance 
• Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype 
• Recall the limitations of existing therapies for ATTR-CM 
• List the advantages of emerging classes of agents being evaluated in ATTR-CM 
   

Programme  

1. Challenge 1 – Identifying ATTR in a Regular Cardiac Clinic 
2. Challenge 2 – Managing Patients with a Mixed Phenotype 
3. Challenge 3 – Disease Modifying Treatment for ATTR-CM 
    

This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the content.